News & Media

Take a look inside our world

Press Releases

Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 2...

Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 20

Teva Releases Q1 2026 Aide Memoire

Teva Releases Q1 2026 Aide Memoire

Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advanc...

Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duv

Teva to Present at the Upcoming Investor Conferences in March

Teva to Present at the Upcoming Investor Conferences in March

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Ext...

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable eff...

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecu...

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive

Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’

Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and ...

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adole

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Deliv...

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering
View all press releases
Previous
Next

Contacts for Media Inquiries

Kelley Dougherty

North America

+1-973-658-0237
Kelley.Dougherty@tevapharm.com

Eden Klein

Israel & Corporate

+972-3-9062645
Eden.Klein@teva.co.il

Fiona Cohen

Europe

fiona.cohen@tevaeu.com

Teva Media Assets

These proprietary media assets are available for download and are intended for non-commercial media use and research only.

Download Logo Download Teva B-Roll

Feature stories

All Access to Medicine Biologics Biosimilars Caregivers Environment Generic Medicines Global Operations Immunology Innovation Leadership Inclusion & Diversity Neuroscience Our People Patient Focus Quality Research & Development Respiratory Sustainability Wellbeing Working at Teva

3 Trends I’m Watching in Pharmaceutical Marketing and Digital

3 Trends I’m Watching in Pharmaceutical Marketing and Digital

Spreading HOPE: Teva’s Work to Improve Global Access to Medicine

Spreading HOPE: Teva’s Work to Improve Global Access to Medicine

Living With an Invisible Disability: What We All Need to Know

Living With an Invisible Disability: What We All Need to Know

Treating the Untreatable: Harnessing Biological Processes to Fight Disease

Treating the Untreatable: Harnessing Biological Processes to Fight Disease

A Passport to Career Development: A Journey with Teva's R&D Teams

A Passport to Career Development: A Journey with Teva's R&D Teams

The Neuroscience of Inclusion and Diversity: Unlocking High-Impact Team Performance

The Neuroscience of Inclusion and Diversity: Unlocking High-Impact Team Performance

Migraine at Work: How it Impacts Us All

Migraine at Work: How it Impacts Us All

What are Biologics and Biosimilars?

What are Biologics and Biosimilars?

Medical Specialists We All Need but Never See: Safety Physicians

Medical Specialists We All Need but Never See: Safety Physicians

3 Trends I’m Watching in Sustainability

3 Trends I’m Watching in Sustainability
View all stories

Connect with us on social media

Follow us on Facebook

Go to facebook.com

Follow us on Linkedin

Go to linkedin.com

Follow us on Twitter

Go to twitter.com

View our Social Media Guidelines

Learn more